This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or pr

Meena is a member of The Motley Fool Blog Network -- entries represent the personal opinions of our bloggers and are not formally edited. The healthcare industry is growing rapidly and healthcare spending is growing at around 8% every year. At that pace,

Biogen Idec ( BIIB ) recently signed a deal to acquire privately-held biotech company, Stromedix, Inc. With this acquisition, Biogen will gain access to treatments being developed for fibrosis and organ failure. The lead candidate at Stromedix is STX-100

Biogen Idec has agreed to acquire five-year-old, privately-held Stromedix Inc for $75 million upfront and up to $487.5 million in milestones. But there is a twist to the buyout, as the research programme at the heart of the startup – which is also behind

The U.S. Food and Drug Administration’s recently issued guidance for development of biosimilars, which could take a bite out of both escalating drug prices and drug company profits, has upped the stakes for intellectual property protection at biotech and

Kyle is a member of The Motley Fool Blog Network -- entries represent the personal opinions of our bloggers and are not formally edited. Greece is saved, right? Let’s go start a fire to show our disapproval. If you think Greece is truly saved, you might

A promising candidate for idiopathic pulmonary fibrosis forms the basis of an acquisition deal between Biogen Idec Inc. and Stromedix Inc. , of Cambridge, Mass. Biogen will pay $75 million up front, and up to $487.5 million in milestones for the company,

WESTON & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) y Stromedix, Inc. han anunciado que han llegado a un acuerdo definitivo por el cual Biogen Idec adquirirá Stromedix Inc. , una empresa biotecnológica de capital privado centrada en inn

Biogen Idec Inc. , a large biotechnology company based in Weston, said it has agreed to buy Stromedix Inc. , a privately held Cambridge firm focused on therapies for fibrosis and organ failure. For more from BostonGlobe.com, sign up or log in below Access

Weston’s Biogen Idec will acquire Cambridge-based Stromedix Inc. , which is developing a drug to treat a deadly scarring of the lungs, in a deal worth as much as $562.5 million depending on regulatory approvals. Brighton-based sneaker maker New Balance ha

The following are the M&A deals, rumors and chatter circulating on Wall Street for Tuesday February 14, 2012: The 13D Filing: Carl Icahn issued the following statement in a 13D filing for CVR Energy (NYSE: CVI): On February 13, 2012, Carl C. Icahn and ot

For anyone wondering about the value that can be added by entrepreneurs and venture capitalists to the drug discovery and development process, look no further than Stromedix. This venture-backed company in Cambridge, MA, was acquired today by Biogen Idec

NEW YORK (AP) — Biogen Idec Inc. said Tuesday it will pay as much as $562.5 million to acquire Stromedix Inc. , a biotechnology firm that is developing treatments for conditions like idiopathic pulmonary fibrosis. Biogen said it will pay $75 million upfro

By Jon Kamp Biogen Idec Inc. said Tuesday it will pay $75 million upfront and as much as $487.5 million in future payments to acquire closely held biotechnology company Stromedix Inc. , which is working on a treatment for damaging scar tissue in the lungs

Earlier today, Biogen Idec agreed to pay up to $562 million, including an upfront payment of $75 million, for Stromedix and its lead drug candidate, STX-100, which is a novel humanized monoclonal antibody that is entering Phase IIa testing to treat idiop

Dow Jones Reprints: This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers, use the Order Reprints tool at the bottom of any article or visit www.djreprints.co

Biogen Idec Inc. of Weston didn’t look far for its latest acquisition - Cambridge-based biotech Stromedix Inc. , which Biogen will purchase for up to a possible $562.5 million, bringing an original Biogen tech back into the fold. The deal calls for an up

All Rights Reserved. This material may not be published, broadcast, rewritten, or redistributed. (AP) NEW YORK Biogen Idec Inc. said Tuesday it will pay as much as $562.5 million to acquire Stromedix Inc. , a biotechnology fir

Google (Nasdaq: GOOG) and Motorola Mobility (NYSE: MMI) received approval from U.S. and European regulators Monday for the proposed $12.5 billion combination. The EU approved the deal, but said it would closely monitor developments moving forward to ensu